Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy
Open Access
- 7 July 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
Abstract
Antibodies are essential molecules for diagnosis and treatment of diseases caused by pathogens and their toxins. Antibodies were integrated in our medical repertoire against infectious diseases more than hundred years ago by using animal sera to treat tetanus and diphtheria. In these days, most developed therapeutic antibodies target cancer or autoimmune diseases. The COVID-19 pandemic was a reminder about the importance of antibodies for therapy against infectious diseases. While monoclonal antibodies could be generated by hybridoma technology since the 70ies of the former century, nowadays antibody phage display, among other display technologies, is robustly established to discover new human monoclonal antibodies. Phage display is an in vitro technology which confers the potential for generating antibodies from universal libraries against any conceivable molecule of sufficient size and omits the limitations of the immune systems. If convalescent patients or immunized/infected animals are available, it is possible to construct immune phage display libraries to select in vivo affinity-matured antibodies. A further advantage is the availability of the DNA sequence encoding the phage displayed antibody fragment, which is packaged in the phage particles. Therefore, the selected antibody fragments can be rapidly further engineered in any needed antibody format according to the requirements of the final application. In this review, we present an overview of phage display derived recombinant antibodies against bacterial, viral and eukaryotic pathogens, as well as microbial toxins, intended for diagnostic and therapeutic applications.Funding Information
- Horizon 2020 Framework Programme
- Seventh Framework Programme
This publication has 510 references indexed in Scilit:
- High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cellsBMC Biotechnology, 2013
- Generation and Characterization of a Novel Recombinant Antibody against LMP1-TES1 of Epstein-Barr Virus Isolated by Phage DisplayViruses, 2013
- Isolation of Recombinant Phage Antibodies Targeting the Hemagglutinin Cleavage Site of Highly Pathogenic Avian Influenza VirusPLOS ONE, 2013
- Diagnostic evaluation of a nanobody with picomolar affinity toward the protease RgpB from Porphyromonas gingivalisAnalytical Biochemistry, 2011
- The Salmonella enterica Pan-genomeMicrobial Ecology, 2011
- A human scFv antibody generation pipeline for proteome researchJournal of Biotechnology, 2011
- Generating recombinant antibodies to the complete human proteomeTrends in Biotechnology, 2010
- A large library based on a novel (CH2) scaffold: Identification of HIV-1 inhibitorsBiochemical and Biophysical Research Communications, 2009
- Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodiesVirology, 2007
- Selection and affinity maturation of IgNAR variable domains targeting Plasmodium falciparum AMA1Proteins-Structure Function and Bioinformatics, 2004